mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria

Recruiting N/A Interventional Study
Sickle Cell Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 Months and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
900 (estimated)
Sponsor
New York University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Large knowledge gaps remain regarding strategies to promote the adoption of hydroxyurea (HU), particularly in sub-Saharan African countries including Nigeria, where more than 75% of annual sickle cell anemia births occur. The vast majority of people with SCD in Africa do not receive evidenced-based health care (e.g., newborn screening, health education, prophylaxis for infection, optimal nutrition…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * SCD patients18 years older that have provided consent; * Pediatric SCD patients aged 12 months to 17 years with an accompanying guardian and have provided informed consent or assent; * Registration in the electronic medical records (EMR) database with clinical charts and recei…
Contacts

Emmanuel Peprah, PhD

212-992-6085

ep91@nyu.edu

CONTACT

Obiageli Nnodu

oennodu@gmail.com

CONTACT